Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $1,153,620.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $320.45, for a total transaction of $1,153,620.00. Following the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $41,658.50. The transaction was disclosed in a filing with the SEC, which is available through this link.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $311.04 on Friday. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $325.00. The firm has a 50 day moving average of $281.11 and a 200-day moving average of $245.82. The company has a market cap of $13.80 billion, a price-to-earnings ratio of 14.71, a price-to-earnings-growth ratio of 1.39 and a beta of 0.55.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. The company had revenue of $677.70 million for the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The business’s revenue was up 33.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $4.86 EPS. On average, equities analysts forecast that United Therapeutics Co. will post 24.73 earnings per share for the current year.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors have recently modified their holdings of UTHR. Rise Advisors LLC bought a new position in shares of United Therapeutics in the first quarter valued at $32,000. GAMMA Investing LLC bought a new position in United Therapeutics during the 4th quarter valued at $43,000. Benjamin F. Edwards & Company Inc. boosted its holdings in United Therapeutics by 63.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 117 shares during the last quarter. Janiczek Wealth Management LLC grew its stake in shares of United Therapeutics by 21.1% in the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 84 shares in the last quarter. Finally, Blue Trust Inc. raised its holdings in shares of United Therapeutics by 10.0% in the fourth quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 46 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

UTHR has been the topic of a number of research reports. The Goldman Sachs Group boosted their price objective on United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 12th. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 20th. Oppenheimer lifted their price target on shares of United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a report on Thursday, May 2nd. Finally, JPMorgan Chase & Co. raised their target price on United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 21st. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $312.22.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.